Cancer stem cell

Results: 652



#Item
1

Laboratory Investigation, 970–982 & 2013 USCAP, Inc All rights reserved $32.00 PATHOBIOLOGY IN FOCUS Patient-derived xenografts, the cancer stem cell

Add to Reading List

Source URL: www.abbvie.com

Language: English - Date: 2018-07-20 14:49:13
    2

    24th NSW Stem Cell Network Workshop Stem Cells and Cancer Darlington Centre City Rd, Sydney Wednesday, April 6th, 2016

    Add to Reading List

    Source URL: www.stemcellnetwork.org.au

    Language: English - Date: 2016-04-11 20:16:04
      3

      Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Car

      Add to Reading List

      Source URL: www.childrensoncologygroup.org

      Language: English - Date: 2017-12-18 08:31:20
        4

        A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

        Add to Reading List

        Source URL: s3.amazonaws.com

        - Date: 2014-09-25 16:14:56
          5

          Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

          Add to Reading List

          Source URL: posters.omed.s3.amazonaws.com

          - Date: 2015-06-12 10:36:45
            6

            Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain

            Add to Reading List

            Source URL: posters.omed.s3.amazonaws.com

            - Date: 2015-11-04 11:34:18
              7

              A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

              Add to Reading List

              Source URL: posters.omed.s3.amazonaws.com

              - Date: 2016-01-22 10:42:40
                8

                A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

                Add to Reading List

                Source URL: s3.amazonaws.com

                - Date: 2014-09-25 16:14:56
                  9

                  Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan

                  Add to Reading List

                  Source URL: posters.omed.s3.amazonaws.com

                  - Date: 2015-11-04 11:34:26
                    10

                    Safety and early evidence of activity of a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with selected solid tumors A.

                    Add to Reading List

                    Source URL: s3.amazonaws.com

                    - Date: 2014-11-19 14:29:45
                      UPDATE